AXIOS platform

Search documents
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
ZACKS· 2025-07-10 13:20
Key Takeaways BSX's MedSurg growth is fueled by endoscopy, neuromodulation, and global urology market share gains. BSX's WATCHMAN sales rose 24% in Q1 2025, driven by new DRG rules and next-gen device adoption. Recent acquisitions added 400bps to Q1 sales and drove 18.2% organic revenue growth for BSX.Boston Scientific’s (BSX) robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN d ...
BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?
ZACKS· 2025-06-26 14:20
Key Takeaways BSX gains MedSurg share via growth in Endoscopy, Urology and Neuromodulation product lines. MDT expands Surgical Robotics with Hugo RAS, now rolled out across 30 international markets. Both BSX and MDT see growth in emerging markets. Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are ...